Physiologically Based Pharmacokinetic (PBPK) modeling in children

J. S. Barrett, O. Della Casa Alberighi, S. Läer, Bernd Meibohm

Research output: Contribution to journalReview article

108 Citations (Scopus)

Abstract

This review summarizes the present status of physiologically based pharmacokinetic (PBPK) modeling and simulation (M&S) and its application in support of pediatric drug research. We address the reasons that PBPK is suited to the current needs of pediatric drug development and pharmacotherapy in light of the evolution in pediatric PBPK methodologies and approaches, which were originally developed for the purpose of toxicologic evaluation. Also discussed is the current degree of confidence in using PBPK to support pediatric drug development and registration and the key factors essential for robust results and broader adoption of pediatric PBPK M&S.

Original languageEnglish (US)
Pages (from-to)40-49
Number of pages10
JournalClinical Pharmacology and Therapeutics
Volume92
Issue number1
DOIs
StatePublished - Jul 1 2012

Fingerprint

Pharmacokinetics
Pediatrics
Pharmaceutical Preparations
Drug Therapy
Research

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Physiologically Based Pharmacokinetic (PBPK) modeling in children. / Barrett, J. S.; Della Casa Alberighi, O.; Läer, S.; Meibohm, Bernd.

In: Clinical Pharmacology and Therapeutics, Vol. 92, No. 1, 01.07.2012, p. 40-49.

Research output: Contribution to journalReview article

Barrett, J. S. ; Della Casa Alberighi, O. ; Läer, S. ; Meibohm, Bernd. / Physiologically Based Pharmacokinetic (PBPK) modeling in children. In: Clinical Pharmacology and Therapeutics. 2012 ; Vol. 92, No. 1. pp. 40-49.
@article{32e4953aab084b52a07b0fb4e2f4e5c7,
title = "Physiologically Based Pharmacokinetic (PBPK) modeling in children",
abstract = "This review summarizes the present status of physiologically based pharmacokinetic (PBPK) modeling and simulation (M&S) and its application in support of pediatric drug research. We address the reasons that PBPK is suited to the current needs of pediatric drug development and pharmacotherapy in light of the evolution in pediatric PBPK methodologies and approaches, which were originally developed for the purpose of toxicologic evaluation. Also discussed is the current degree of confidence in using PBPK to support pediatric drug development and registration and the key factors essential for robust results and broader adoption of pediatric PBPK M&S.",
author = "Barrett, {J. S.} and {Della Casa Alberighi}, O. and S. L{\"a}er and Bernd Meibohm",
year = "2012",
month = "7",
day = "1",
doi = "10.1038/clpt.2012.64",
language = "English (US)",
volume = "92",
pages = "40--49",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Physiologically Based Pharmacokinetic (PBPK) modeling in children

AU - Barrett, J. S.

AU - Della Casa Alberighi, O.

AU - Läer, S.

AU - Meibohm, Bernd

PY - 2012/7/1

Y1 - 2012/7/1

N2 - This review summarizes the present status of physiologically based pharmacokinetic (PBPK) modeling and simulation (M&S) and its application in support of pediatric drug research. We address the reasons that PBPK is suited to the current needs of pediatric drug development and pharmacotherapy in light of the evolution in pediatric PBPK methodologies and approaches, which were originally developed for the purpose of toxicologic evaluation. Also discussed is the current degree of confidence in using PBPK to support pediatric drug development and registration and the key factors essential for robust results and broader adoption of pediatric PBPK M&S.

AB - This review summarizes the present status of physiologically based pharmacokinetic (PBPK) modeling and simulation (M&S) and its application in support of pediatric drug research. We address the reasons that PBPK is suited to the current needs of pediatric drug development and pharmacotherapy in light of the evolution in pediatric PBPK methodologies and approaches, which were originally developed for the purpose of toxicologic evaluation. Also discussed is the current degree of confidence in using PBPK to support pediatric drug development and registration and the key factors essential for robust results and broader adoption of pediatric PBPK M&S.

UR - http://www.scopus.com/inward/record.url?scp=84862617981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862617981&partnerID=8YFLogxK

U2 - 10.1038/clpt.2012.64

DO - 10.1038/clpt.2012.64

M3 - Review article

VL - 92

SP - 40

EP - 49

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -